Powered by

Neon Therapeutics Expands Board of Directors with Leading Experts in Cancer Drug Discovery and Corporate Finance

Dec 12, 2017 - Business Wire

Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the expansion of the company's Board of Directors with the addition of leading experts in translational cancer drug discovery and corporate finance.

Julian Adams, Ph.D., an accomplished scientist with a successful track record of drug discovery and development, and Meryl Zausner, former chief financial and administrative officer of Novartis, and will help to guide the compa...